Sep 2026· International Journal of Molecular Sciences· Vol 27, pp. 8469· 0 citations· 23 references
Advanced biosensing and bioanalysis techniques
TL;DR
Local fitting returns internally consistent KD for data incompatible with a 1:1 model; it is proposed isotherm verification and antibody validation of every preparation as minimal requirements.
Abstract
An aptamer’s low mass confines the label-free response to hundredths of a nanometer, where artifacts mimic binding yet yield computable dissociation constants. To define and test a priori criteria distinguishing binding from artifact, 88 computationally designed aptamers against seven human proteins were studied by biolayer interferometry in two orthogonal configurations, with control antibodies. Six criteria, fixed in advance, are reported as a priori decision rules, not validated requirements. Control antibodies validated 6 of 8 preparations; for the other 68 pairs, the maximum response was 0.019–0.219 nm, bounding KD at ≥8.6 µM, 120-fold above the 70 nM threshold. Two of three signals clearing it gave exponents far above the 1:1 expectation (1.04 vs. 0.31; 0.85 vs. 0.41); the third failed parameter consistency (KD scatter ×28). Rankings on two PCSK9 preparations did not correlate (ρ = −0.26); predicted and experimental KD differed by 3–7 orders of magnitude (ρ = 0.497, n = 25). No aptamer reached the predefined affinity under the conditions tested. Local fitting returns internally consistent KD for data incompatible with a 1:1 model; we propose isotherm verification and antibody validation of every preparation as minimal requirements. No positive-control aptamer was available, limiting interpretation.
Aptamer development has traditionally relied on iterative, labor-intensive experimental approaches. Recent advances in bioinformatics and computational power now enable the rational in silico design of high-affinity nucleic acid ligands, drastically reducing time and cost. Here, we present an integrated computational p...
José C. E. Márquez Montesinos, Ana Maria Bernardez, Yuliet Mazola et al.· Biomolecules· 0 citations
The concept of mimic antibodies–antibodies that recapitulate the binding mode of a target’s cognate ligand is investigated and established as a promising strategy for rational antibody selection, engineering, and design, with broad implications for therapeutic antibody development and drug discovery.
Brennan Abanades, Joanan López-Morales, Ivana Tanasijević et al.· mAbs· 2 citations
Efficient evaluation of aptamer candidates after systematic evolution of ligands by exponential enrichment (SELEX) remains limited by the time and cost required for direct kinetic characterization. We developed a centrifugal microspin filtration (MSF)-based MSF–koff assay for retention-based, dissociation-sensitive pre...
Cheeyoon Ahn, H. Jeong, K. Jeon et al.· Biosensors· 0 citations
Results indicate that folding landscape organization can be used as a predictor of aptamer activity and establish RCI as a simple, mechanistically interpretable measure for improving candidate prioritization, especially in therapeutic aptamer discovery.
Gopalakrishnan Subramanian, William H. Thiel, Rahul Singh· bioRxiv· 0 citations
MOTIVATION
Antibody-antigen (Ab-Ag) interactions are central to immune recognition and widely exploited in therapeutic design, making accurate structural characterization of these complexes a central challenge in the field. While docking and artificial intelligence-based approaches can generate multiple candidate bindi...
Júlia S. Souza, Aline O. Albuquerque, Diego Almeida et al.· Bioinformatics· 0 citations
ABSTRACT Biophysical methods are widely used for drug discovery, with surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) being amongst the most used techniques. However, these types of bulk or ensemble methods do not provide single-molecule resolution or structural and mechanistic insights, so t...
Zhen Wang, Henning Labuhn, R. Moulinas et al.· RNA Biology· 0 citations
A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.